Posttransplant lymphoproliferative disorders

Rare Hematological Malignancies

Volumn , Issue , 2008, Pages 273-292

  Habermann, Thomas M ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; GRAFT REJECTION; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGY; LYMPHOPROLIFERATIVE DISEASE; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATION; REVIEW;

ADULT; GRAFT REJECTION; HUMANS; IMMUNOCOMPROMISED HOST; LYMPHOPROLIFERATIVE DISORDERS; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS;

EID: 84892819512     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-73744-7_12     Document Type: Chapter

References (122)

1. Starzl TE. Discussion of Murray JE, Wilson RE, Tilney NL, et al. Five years' experience in renal transplantation with immunosuppressive drugs: survival, function, complications and the role of lymphocyte depletion by thoracic duct fistula. Ann Surg 1968;168:416-435.
2. Penn I. Posttranspantation de novo tumors in liver allograft recipients. Liver Transplant Surg 1996;2:52-59.
3. Penn I. Cancers complicating organ transplantation. N Engl J Med 1990:323:1767-1769.
4. Hanto DW. Classification of Epstein-Barr virus associated post-transplant lymphoproliferative diseases: mplications for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med 1995;46:381-394.
5. Nalesnik MA. Post-transplanation lymphoproliferative disorders (PTLD): current perspectives. Semin Thorac Cardiovasc Surg 1996;8:139-148.
6. Morrison VA, Dunn DL, Manivel LC, et al. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 1994;97:14-24.
7. Paya C V, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced post-transplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and the Mayo Clinic Organized International Consensus Development Meeting. Transplantation. November 27, 1999;68(10):1517-1525.
8. Leblond V, Choquet S. Lymphoproliferative disorders after liver transplantation. J Hepatol 2004;40:728-735.
9. Kremers WK, Devarbhavi HC, Wiesner RH, et al. Post-transplant lymphoproliferative disorders following liver transplantation: Incidence, risk factors and survival. Am J Transplant 2006;6:1017-1024.
10. Habermann TM, Steensma DP. Lymphadenopathy. Mayo Clin Proc 2000;75:723-732.
11. Leblond V, Dhedin N, Marnzer Bruneel MF, et al. Identification of prognosticfactors in 61 patients with posttransplant lymphoproliferative disorders. J Clin Oncol 2001;19:772-778.
12. Benkerrou M J J, Jais JP, Leblond V, et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome. Blood 1998;92:3137-3147.
13. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988;133:173-192.
14. Ghobrial IM, Habermann TM, Maurer MJ, et al. Prognostic analysis for survival in adult solid organ transplant recipients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2005;23:7574-7582.
15. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000;343(7):481-492.
16. Leblond V, Davi F, Charlotte F, et al. Post-transplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 1998;16(6):2052-2059.
17. Nelson BP, Nalesnik MA, Bahler DW, et al. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol 2000;24(3):375-385.
18. Dotti G, Fiocchi R, Motta T, et al. Epstein-Barr virus-negative lymphoproliferative disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation. March 15, 2000;69(5):827-833.
19. Swerdlow AJ, Higgins CD, Hunt BJ, et al. Risk of lymphoid neoplasia after cardiothoracic transplantation. A cohort study of the relation to Epstein-Barr virus. Transplantation. March 15, 2000;69(5):897-904.
20. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000;343:481-492.
21. Glickman JN, Howe JG, Steitz JA. Structural analysis of EBER1 and EBER2 ribonucleoprotein particles present in Epstein-Barr virus-infected cells. J Virol 1988;62:902-911.
22. Walker RC, Marshall WF, Strickler JG, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infec Dis 1995;20(5):1346-1353.
23. Straus SE, Cohen JI, Tosato G, et al. NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management. Ann Intern Med 1993;118:45-58.
24. Yang J, Tao Q, Flinn IW, et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 2000;96(13):4055-4063.
25. Spiro IJ, Yandell DW, Li C, et al. Brief report: lymphoma of donor origin occurring in the porta hepatitis of a transplanted liver. N Engl J Med 1993;329(1):27-29.
26. Ho M, Miller G, Atchinson RW, et al. Epstein-Barr virus infection and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis 1985;152:876-886.
27. Weissmann DJ, Ferry JA, Harris NL, et al. Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin. Am J Clin Pathol 1995;103:748-755.
28. Chadbum A, Suciu-Foca N, Cesarman E, et al. Post-transplantation lymphoproliferative disorders arising in solid organ transplant recipients are usually of recipient origin. Am J Clin Pathol 1995;1862-1870.
29. Muti G, Veronese S, Poli F, et al. Donor or recipient origin of post-transplant lymhoproliferative disorders in liver transplanted patients: two different, clinically relevant, patterns of disease. Blood 2003;102:629a.
30. Geis WP, Iwatsuki S, Molnar Z, et al. Pseudolymphoma in renal allograft recipients. Arch Surg 1978;113:461-466.
31. Fizzera G, Hanto DW, Gajl-Peczalska RJ, et al. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 1981;41:4262-4279.
32. Harris N, Swerdlow S, Frizzera G, Knowles D. Post-transplant lymphoproliferative disorders. In: Jaffe E, Harris N, Stein H, Vardiman J. editors. World Health Organization classification of tumours. Pathology and genetics of hematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. p. 264-269.
33. Nalesnik MA. The diverse pathology of post-transplant lymphoproliferative disorders: The importance of a standardized approach. Transplant Infect Dis 2001;3:88-96.
34. Rae D, Delecluse HJ, Hamilton-Dutoit SJ, et al. Epstein-Barr virus latent and replicative gene expression in post-transplant lymphoproliferative disorders and AIDS-related non-Hodgkin's lymphomas. French Study Group of Pathology for HIV-associated Tumors. Ann Oncol 1994;5(Suppl 1):113-116.
35. Badley AD, Portela DF, Patel R, et al. Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder. Transplant Surg 1996;2:375-382.
36. Wagner HJ, Fischer L, Jabs WJ, et al. Longitudinal analysis of Epstein-Barr load in plasma and peripheral blood mononuclear cells of transplanted patients by real-time polymerase chain reaction. Transplantation 2002;74:656-664.
37. Gera M, Habermann TM, Stegall MD, et al. Viral DNA quantification in EBV-mismatched kidney transplant recipients: utility for early detection of PTLD. The 2006 World Transplant Congress, 2006. p. 416a.
38. Armitage JM, Kormos RL, Stuart RS, et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991;10:877-887.
39. Alfrey EJ, Freidman AL, Grossman RA, et al. A recent decrease in the time to development of monomorphous and polymorphous post-transplant lymphoproliferative disorder. Transplantation 1992;54:250-253.
40. Au W Y, Lie AK, Lee CK, et al. Late onset post-transplantion lymphoproliferative disease of recipietn origin following cytogenetic relapse and occult autologous heamatopoietic regeneration after allogeneic bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 2001;28:417-419.
41. Nalesnik MA. Clinicopathologic characteristics of post-transplant lymphoproliferative disorders. Recent Results Cancer Res 2002;159:9-18.
42. Nelson BP, Nalesnik MA, Bahler DW, et al. Epstein-Barr virus negative post-transplant lymphoproliferative disorders: A distinct entity? Am J Surg Pathol 2000;24:375-385.
43. Ghobrial IM, Habermann TM, Macron WR, et al. Differences between early and late post-transplant lymphoproliferative disorders in solid organ transplant patients: Are they two different diseases? Transplantationb 2005;79(2):244-247.
44. Horwitz SM, Ranheim EA, Morgan DS, et al. A unified approach to posttransplant lymphoproliferative disorder (PTLD): improved outcome and analysis of prognostic factors (Abstract 2295). Blood 1999;94(Suppl 1):10.
45. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004;4:222-230.
46. Finn L, Reyes J, Bueno J, et al. Epstein-Barr virus infections in children after transplantation of the small intestine. Am J Surg Pathol 1998;22:299-309.
47. Swinnen LJ, Costatanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990;323:1723-1728.
48. Cockfield S M A, Preiksaitis JK, Jewell LD, et al. Post-transplant lymphoproliferative disorder in renal allograft recipients. Transplantaion 1993;56:88-96.
49. Benkerrou M J J, Jais JP, Leblond V, et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome. Blood 1998;92:3137-3147.
50. Choquet S, Marnzer BM, Hermine O, et al. Identification of prognostic factors in post-transplant lymphoproliferative disorders. Recent Results Cancer Res 2002;159:67-80.
51. Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001;71:1076-1088.
52. Muti G, Cantoni S, Oreste P, et al. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment. Haematologica 2002;87:67-77.
53. Horwitz SM, Ranheim EA, Morgan DS, et al. A unified approach to posttransplant lymphoproliferative disorder (PTLD): improved outcome and analysis of prognostic factors. Blood 1999;94:513a.
54. The International Non-Hodgkin's Lymphoma Prognostic Factor Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
55. Shapiro RS, McClain K, Frizzera G, et al. Epstein-Barr virus associated B-cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988;71:1234-1243.
56. Darnekov IA, Marcarelli MA, Basadonna GP, et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemtive antiviral therapy. Transplantation 1997;64:848-852.
57. Davis CL, Harrison KL, McVicar JP, et al. Antiviral prophylaxsis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder. Clin Transplant 1995;9:53-59.
58. Gross TG, Steinbuch M, De For T, et al. B-cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant 1999;23:251-258.
59. Green M, Bueno J, Rowe D, et al. Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children. Transplantation 2000;70:593-596.
60. McDiarmid SV, Jordan S, Kim GS, et al. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998;66:1604-1611.
61. Humar A, Herbert D, Davies HD, et al. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxsis against Epstein-Barr virus related posttransplant lymphoproliferative disorder. Transplantation 2006;81:856-861.
62. Kang SK, Kirkpatrick JP, Halperin EC. Low-dose radiation for posttransplant lymphoproliterative disorder. Am J Clin Oncol 2003;26:210-214.
63. Penn I. Immunosuppression-a contributory factor in lymphoma formation. Clin Transplant 1992;6:214-219.
64. Benkerrow M, Durandy A, Fischer A. Therapy for transplant-related lymphoproliferative diseases. Hematol Oncol Clin North Am 1993;7:467-475.
65. Starzl TE, Porter KA, Iwatsuki S, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancer 1984;1:583.
66. Heslop HE, Brenner MK, Rooney C, et al. Administration of neomycin-resistancegene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. Hum Gene Ther 1994;5:381-397.
67. Loren AW, Tsai DE. Post-transplant lymphoproliferative disorder. Clin Chest Med 2005;26:631-645.
68. Taylor AL, Marcus R, Bradley JA, et al. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 2005;56:155-167.
69. Green M. Management of Epstein-Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation. Am J Transplant 2001;1:103-108.
70. Doti G, Fiocchi R, Motta T, et al. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol 2000;24:375-385.
71. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833.
72. Coffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346:235-242.
73. Habermann TM, Weller E, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-3127.
74. Milpied N, Vasseur B, Antoine B, et al. Post-transplant lymphoproliferative disorder. Chimeric anti-CD20 monoclonal antibody (rituximab) in B-post-transplant lymphoproliferative disorders: A retrospective analysis of 32 patients (Abstract 2803). Blood 1999;94:631A.
75. Milpied N, Vasseur B, Parquet, et al. Humanized anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder: a retrospective analysis of 32 patients. Ann Oncol 2000;11:113-116.
76. Cook R, Connors JM, Gascoyne RD, et al. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation. Lancet 1999;354:1698-1699.
77. Gonzalez-Barca E, Domingo-Domenech E, Gomez-Codina J, et al. First-line treatment with rituximab improves survival of patients with post-transplant lymphoproliferative disease (PTLD). Blood 2004;104:394a.
78. Ghobrial IM, Habermann TM, Ristow KM, et al. Prognostic factors in patients with posttransplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma 2005;46:191-196.
79. Elstrom RI, Andreadis C, Aqui NA, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006;6:569-576.
80. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell posttransplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006;107:3053-3057.
81. Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005;5:2901-2906.
82. Orjeula M, Gross TG, Cheung YK, et al. A pilot study of chemoimmunotherapy (cylophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation. Clin Cancer Res 2003;9:3945S-3952S.
83. Voog E, Morschhauser F, Solal-Celigny P, et al. Neutropenia in patients treated with rituximab. N Engl J Med 2003;348:2691-2694.
84. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001;344:68-69.
85. Sharma VR, Fleming DR, Slone SP. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 2000;96:1184-1186.
86. Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantion lymphoproliferative disorder. N Engl J Med 2001;345:1000.
87. Hochster HS, Weller E, Gascoyne RD, et al. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): Results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood 2005;106:196a.
88. van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002;99:4364-4369.
89. Hanto DW, Frizzera G, Galj-Peczalska, et al. Epstein Barr virus, immunodeficiency, and B-cell lymphoproliferation. Transplantation 1985;39:461-472.
90. Raymond E, Tricottet V, Samuel D, et al. Epstein-Barr virus-related lymphoproliferative disorders treated with cyclophosphamide-doxorubicin- vincristine-prednisone chemotherapy. Cancer 1995;72:1344-1351.
91. Lien Y-H, Schroter G P J, Weil R III, et al. Complete remission and possible immune tolerance after multidrug combination chemotherapy for cyclosporine-related lymphoma in a renal transplant patient with acute pancreatitis. Transplantation 1991;52:739-742.
92. Garrett TJ, Chadburn A, Barr ML, et al. Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin- vincristine-prednisone chemotherapy. Cancer 1993;72:2782-2785.
93. Swinnen LJ, Mullen GM, Carr TJ, et al. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995;86:3333-3340.
94. Van Gorp J, Doornewaard H, Verdonck LF, et al. Post-transplant T-cell lymphoma. Cancer 1994;73:3064-3072.
95. Hanson MN, Morrison VA, Peterson BA, et al. Posttransplant T-cell lymphoproliferative disorders-an aggressive, late complication of solid-organ transplantation. Blood 1996;88:3626-3633.
96. Dotti G, Fiocchi R, Motta T, et al. Lymphomas occurring late after solid-organ transplantaion: influence of treatment on the clinical outcome. Transplantation 2002;74:1095-1102.
97. Buell JF, Gross TG, Hanaway MJ, et al. Chemotherapy for posttransplant lymphoproliferative disorder: the Isreal Penn International Transplant Tumor Registry experience. Transplant Proc 2005;37:956-957.
98. Gross TG, Bucuvalas JC, Park JR, et al. Low-dose chemotherapy for Epstein-Barr viruspositive post-transplantation lymphoptoliferative disease in children after solid organ transplantation. J Clin Oncol 2005;23:6481-6488.
99. Oertel SH, Papp-Vary M, Anagnostopoulos I, et al. Salvage chemotherapy for refractory or relapsed post-transplant lymphoproliferative disorder in patients after solid organ transplantation with a combination of carboplatin and etoposide. Br J Haematol 2003;123:830-835.
100. Komrokji RS, Oliva JL, Zand M, et al. Mini-BEAM and autologous hematopoietic stem-cell transplant for treatment of post-transplant lymphoproliferative disorders. Am J Hematol 2005;79:211-215.
101. Bobey NA, Stewart DA, Woodman RC, et al. Successful treatment of posttransplant lymphoproliferative disorder in a renal transplant patient by autologous peripheral blood stem cell transplantation. Leuk Lymphoma 2002;43:2421-2423.
102. Tosato G, Tanner J, Jones KD, et al. Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells. J Virol 1990;64:3033-3041.
103. Tosato G, Jones K, Breinig MK, et al. Interleukin-6 production in posttransplant lymphoproliferative disease. J Clin Invest 1003;91:2906-2814.
104. Haddad E, Paszesny S, Leblond V, et al. Treatment of B- lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood 2001;97:1590-1597.
105. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;330:1165-1191.
106. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998;92:1549-1555.
107. Gulley ML, Swinnen LJ, Plaisance KT, et al. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy. Transplantation 2003;76:959-964.
108. Nalesnik MA, Rao AS, Furukawa H, et al. Autologous lymphokine activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 2002;99:2592-2598.
109. Comoli P, Labirio M, Basso S, et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active viral replication. Blood 2002;99:2592-2598.
110. Comoli P, Maccario R, Locatelli F, et al. Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells. Am J Transplant 2005;5:1415-1422.
111. Haque T, Amlot PL, Helling N, et al. Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients. J Immunol 1998;160:6204-6209.
112. Khanna R, Bell S, Sherritt M, et al. Activation and adoptive transfer of Epstein-Barr virusspecific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci USA 1999;96:10, 391-10, 396.
113. Sherritt MA, Bharadwaj M, Burrows JM, et al. Resconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from transplant lymphoma after adoptive immunotherapy. Transplantaion 2003;75:1556-1560.
114. Savoldo B, Gross JA, Hammer MM, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 2006;108:2942-2949.
115. Metes D, Storkus W, Zeevi A, et al. Ex vivo generation of effective Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocytes from the peripheral blood of immunocompetent Epstein Barr virus-seronegative individuals. Transplantation 2000;70:1507-1515.
116. Popescu I, Macedo C, Zeevi A, et al. Ex vivo priming of naive T cells into EBV-specific Th1/Tc1 effector cells by mature autologous DC loaded with apoptotic/necrotic LCL. Am J Transplant 2003;3:1369-1377.
117. Haque T, Wilkie GM, Taylor C, et al. Treatment of Epstein-Barr-virus- positive posttransplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002;360;436-442.
118. Wilkie GM, Taylor C, Jones MM, et al. Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of Epstein-Barr virus-associated diseases. J Immunother 2004;27:309-316.
119. Cesarman E, Chadburn A, Yi-Fang Liu, et al. BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcomes. Blood 1998;92:2294-2302.
120. Capello D, Cerri M, Muti G, et al. Molecular histgenesis of posttransplantation lymphoproliferative disorders. Blood 2003;102:3775-3785.
121. Gasink LB, Blumberg EA, Lacalio AR, et al. Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients. JAMA 2006;296:1843-1850.
122. Majewski M, Korecka M, Kossev P, et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo; a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA 2000;97:4285-4290.